The Boston Herald outlined the following:
The experimental antibody cocktail given to President Trump to help battle his coronavirus — called REGN-COV2 — just this week showed promise. He’s also taking remdesivir.
“Regeneron’s (NASDAQ: REGN) antibody cocktail REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients,” said Dr. George D. Yancopoulos, president and chief scientific officer of Regeneron.
Remdesivir is “a broad-spectrum antiviral,” writes the drug-maker Gilead (NASDAQ: GILD). It has been OK’d for use by the FDA under an emergency use declaration. It’s used for people in the early stages of COVID19.
It’s not as controversial as hydroxychloroquine, that sparked debate when the president touted it during coronavirus task force press conferences.
Here is a company with a product that does not require such a stringent approval and is actually making great headway while just beginning to show up on investors radar.
Take a look at Glucose Health, Inc. (OTC Pink: GLUC). Glucose Health manufacturers nutritional beverages for the diabetic-adult nutrition consumer retail category under the registered trademark GLUCODOWN®.
Now… more than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released by the Centers for Disease Control and Prevention (CDC).
Despite being on the shelves of Walmart (NYSE: WMT), CVS Health (NYSE: CVS) and online at Amazon.com (NASDAQ: AMZN), GLUC is still trading below a $30 million valuation.
GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.
See all of their products here;
Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.
What are the revenues of this company going to look like when the latest GLUCODOWN® numbers are reported for Q3 and Q4?
Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.